Scientific Reports (Mar 2023)

Maximum dose, safety, tolerability and ketonemia after triheptanoin in glucose transporter type 1 deficiency (G1D)

  • Ignacio Málaga,
  • Adrian Avila,
  • Sharon Primeaux,
  • Raja Reddy Kallem,
  • Charles R. Roe,
  • William C. Putnam,
  • Jason Y. Park,
  • Shlomo Shinnar,
  • Chul Ahn,
  • Juan M. Pascual

DOI
https://doi.org/10.1038/s41598-023-30578-z
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 10

Abstract

Read online

Abstract Augmentation of anaplerosis, or replenishment of carbon lost during intermediary metabolic transitions, is desirable in energy metabolism defects. Triheptanoin, the triglyceride of 7-carbon heptanoic acid, is anaplerotic via direct oxidation or 5-carbon ketone body generation. In this context, triheptanoin can be used to treat Glucose transporter type 1 deficiency encephalopathy (G1D). An oral triheptanoin dose of 1 g/Kg/day supplies near 35% of the total caloric intake and impacted epilepsy and cognition in G1D. This provided the motivation to establish a maximum, potentially greater dose. Using a 3 + 3 dose-finding approach useful in oncology, we studied three age groups: 4–6, 6.8–10 and 11–16 years old. This allowed us to arrive at a maximum tolerated dose of 45% of daily caloric intake for each group. Safety was ascertained via analytical blood measures. One dose-limiting toxicity, occurring in 1 of 6 subjects, was encountered in the middle age group in the context of frequently reduced gastrointestinal tolerance for all groups. Ketonemia following triheptanoin was determined in another group of G1D subjects. In them, β-ketopentanoate and β-hydroxypentanoate concentrations were robustly but variably increased. These results enable the rigorous clinical investigation of triheptanoin in G1D by providing dosing and initial tolerability, safety and ketonemic potential. ClinicalTrials.gov registration: NCT03041363, first registration 02/02/2017.